Wall Street brokerages expect Spark Therapeutics Inc (NASDAQ:ONCE) to post sales of $9.53 million for the current fiscal quarter, Zacks reports. Six analysts have made estimates for Spark Therapeutics’ earnings. The lowest sales estimate is $1.50 million and the highest is $21.30 million. Spark Therapeutics reported sales of $16.30 million during the same quarter last year, which indicates a negative year-over-year growth rate of 41.5%. The firm is expected to report its next quarterly earnings results on Wednesday, February 28th.

According to Zacks, analysts expect that Spark Therapeutics will report full-year sales of $9.53 million for the current year, with estimates ranging from $4.66 million to $25.96 million. For the next year, analysts anticipate that the company will post sales of $99.90 million per share, with estimates ranging from $32.25 million to $223.80 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Spark Therapeutics.

Spark Therapeutics (NASDAQ:ONCE) last posted its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($1.90) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.11). Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. The firm had revenue of $1.90 million during the quarter, compared to analyst estimates of $1.40 million. During the same period in the prior year, the company posted ($1.07) earnings per share. The firm’s revenue for the quarter was up 45.8% compared to the same quarter last year.

ONCE has been the subject of a number of recent research reports. Royal Bank of Canada reaffirmed a “buy” rating on shares of Spark Therapeutics in a research note on Wednesday, October 25th. UBS Group downgraded Spark Therapeutics from a “buy” rating to a “neutral” rating and cut their target price for the stock from $92.00 to $51.00 in a research note on Tuesday, December 12th. Raymond James Financial initiated coverage on Spark Therapeutics in a research note on Thursday, October 12th. They issued an “outperform” rating and a $96.00 target price for the company. Cantor Fitzgerald set a $105.00 target price on Spark Therapeutics and gave the stock a “buy” rating in a research note on Monday, December 11th. Finally, Leerink Swann downgraded Spark Therapeutics from an “outperform” rating to a “market perform” rating and set a $49.00 target price for the company. in a research note on Tuesday, December 12th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and fifteen have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $76.03.

Shares of Spark Therapeutics (ONCE) traded down $1.28 on Wednesday, hitting $50.56. The company’s stock had a trading volume of 1,343,879 shares, compared to its average volume of 1,470,000. Spark Therapeutics has a twelve month low of $41.06 and a twelve month high of $91.75. The firm has a market cap of $1,820.00 and a P/E ratio of -7.02.

In related news, insider Katherine A. High sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, October 31st. The stock was sold at an average price of $83.30, for a total transaction of $416,500.00. Following the completion of the transaction, the insider now directly owns 215,000 shares in the company, valued at approximately $17,909,500. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Stephen W. Webster sold 10,000 shares of the firm’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $70.14, for a total value of $701,400.00. Following the transaction, the chief financial officer now owns 12,500 shares of the company’s stock, valued at $876,750. The disclosure for this sale can be found here. Insiders have sold a total of 62,309 shares of company stock valued at $4,621,085 over the last 90 days. 7.30% of the stock is currently owned by company insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. boosted its stake in shares of Spark Therapeutics by 11.6% in the 2nd quarter. BlackRock Inc. now owns 2,053,734 shares of the biotechnology company’s stock valued at $122,689,000 after buying an additional 213,520 shares during the period. Vanguard Group Inc. boosted its stake in shares of Spark Therapeutics by 5.3% in the 2nd quarter. Vanguard Group Inc. now owns 1,924,463 shares of the biotechnology company’s stock valued at $114,968,000 after buying an additional 96,803 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Spark Therapeutics by 15.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock valued at $164,986,000 after buying an additional 241,016 shares during the period. Janus Henderson Group PLC boosted its stake in shares of Spark Therapeutics by 46.4% in the 3rd quarter. Janus Henderson Group PLC now owns 756,088 shares of the biotechnology company’s stock valued at $67,413,000 after buying an additional 239,723 shares during the period. Finally, Orbimed Advisors LLC purchased a new position in shares of Spark Therapeutics in the 3rd quarter valued at about $38,340,000. Institutional investors and hedge funds own 94.91% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was originally published by Marea Informative and is owned by of Marea Informative. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://www.mareainformativa.com/spark-therapeutics-inc-once-expected-to-announce-quarterly-sales-of-9-53-million-updated-updated-updated/124541/.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Get a free copy of the Zacks research report on Spark Therapeutics (ONCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.